SOURCE: Generex Biotechnology Corporation

November 08, 2005 16:00 ET

Generex Biotechnology to Present Clinical Trial Results at the Fifth Annual Diabetes Technology Meeting

TORONTO -- (MARKET WIRE) -- November 8, 2005 -- Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery, today announced that clinical trial results in respect of Oral-lyn™, its proprietary oral insulin spray product, will be presented at the Fifth Annual Diabetes Technology Meeting to be held in San Francisco from November 10 - 12, 2005. The following poster presentations will be made on Thursday, November 10, 2005:

--  "A 12-Day Comparison of Preprandial Humulin® vs. Oral-lyn™ in 10
    Type 1 Diabetic Subjects Receiving Baseline Glargine Insulin Therapy," a
    study coauthored by Dr. Jaime Guevara-Aguirre, Marco Guevara, and Jeannette
    Saavedra, all of the Institute of Endocrinology IEMYR in Quito, Ecuador;
--  "Addition of Oral-lyn™ at Mealtimes in Subjects with Type 2
    Diabetes Maintained on Glargine + Metformin - A Comparison with Placebo," a
    study coauthored by Professor Itamar Raz of Hadassah Hospital, Jerusalem,
    Israel together with M. Kidron (also of Hadassah Hospital) and M. Dubinsky
    and J. Wainstein of Wolfson Hospital, Holon, Israel.
The Meeting's goal is to assemble technology developers and users to facilities creation of new and cost-effective tools to help people with diabetes. The Meeting will place particular emphasis on original data.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, oral insulin (Oral-lyn™), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world.

For more information, visit the Generex Web site at

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Contact Information

  • Shayne Gilliatt
    Generex Biotechnology Corporation

    Ed Lewis
    CEOcast, Inc.
    Email Contact
    for Generex Biotechnology Corporation